New Compound May Decrease Vision Loss In Diabetes

... A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association''s journal Diabetes brings hopeful news to the 18 million people in the United States -- and millions more worldwide -- with type 1 or type 2 diabetes. Initial results of the Phase III clinical trial demonstrated that 32 milligrams per day of ruboxistaurin (RBX) was well tolerated and may reduce the risk of moderate vision loss, especially in patients with diabetic macular edema. ...